Drug - International Biopharmaceutical Industry

Volume 5 Issue 3

ADCs – From Lab to Clinical Development

Antibody-drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. Compared to traditional small-molecule approaches, ADCs offer...

12 October 2022 Volume 5 Issue 3 agents | Antibody

Continue Reading →

news

Upstream Bio, a richly funded startup, reveals its lead drug and research plans

An inflammatory disease drug cast aside by Astellas Pharma has a new owner in Upstream Bio, an emerging biotechnology startup led by industry veteran Samantha Truex a...

6 June 2022 news BIO | Drug

Continue Reading →

news

Regeneron buys control of cancer drug Libtayo from Sanofi

Dive Brief: Regeneron will pay partner Sanofi $900 million to gain global rights to the companies’ cancer immunotherapy Libtayo, announcing Thursday a deal executi...

6 June 2022 news cancer | Drug

Continue Reading →

news

Mirati matches Amgen with updated data for KRAS-blocking cancer drug

Mirati Therapeutics hopes to later this year win U.S. approval of only the second drug able to target tumors spurred by mutations in an elusive gene called KRAS. Upd...

30 May 2022 news Amgen | cancer

Continue Reading →

news

Trial setback casts doubt on a biotech’s respiratory virus drug

Dive Brief: Enanta Pharmaceuticals’ pill to combat respiratory syncytial virus didn’t work in low-risk patients, with the company reporting Wednesday the antiviral...

22 May 2022 news Biotech | Drug

Continue Reading →

news

Key Bristol Myers drug holds up in long-term psoriasis study

Dive Brief: An experimental psoriasis drug developed by Bristol Myers Squibb maintained its effectiveness over more than a year of treatment in a clinical trial ex...

13 May 2022 news Bristol | Drug

Continue Reading →

news

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

Dive Brief: A drug combination including Roche’s experimental immunotherapy tiragolumab failed one of two main goals in a Phase 3 trial in a common form of lung ca...

13 May 2022 news cancer | Drug

Continue Reading →

news

Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug

Dive Brief: Taiho Pharmaceutical is buying back rights to an experimental cancer drug aimed at a genetic driver of lung tumors after licensing it to Cullinan Oncol...

13 May 2022 news cancer | Cullinan

Continue Reading →

news

With spotlight on FDA, Congress weighs reforms to accelerated drug approvals

Over the past few years, the Food and Drug Administration has come increasingly under scrutiny for its program to grant speedy approvals to drugs that show early sign...

13 May 2022 news approvals | Congress

Continue Reading →

news

Biogen CEO to step down as company pulls back from Alzheimer’s drug

Biogen is searching for a new CEO along with additional ways to cut costs after another quarter of paltry sales for its closely watched Alzheimer’s disease drug. Onc...

9 May 2022 news Alzheimer | Biogen

Continue Reading →

Current Edition

Upcoming Events

Advertisement

ADCs – From Lab to Clinical Development

Upstream Bio, a richly funded startup, reveals its lead drug and research plans

Regeneron buys control of cancer drug Libtayo from Sanofi

Mirati matches Amgen with updated data for KRAS-blocking cancer drug

Trial setback casts doubt on a biotech’s respiratory virus drug

Key Bristol Myers drug holds up in long-term psoriasis study

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug

With spotlight on FDA, Congress weighs reforms to accelerated drug approvals

Biogen CEO to step down as company pulls back from Alzheimer’s drug

International Biopharmaceutical Industry